Searched for
XGEVA
Biocon rolls out two biosimilars in US marketBiocon has launched two new biosimilar medicines, Bosaya and Aukelso, in the United States. These drugs treat serious bone conditions. They...- Dr. Reddy’s Laboratories shares jump over 1% as European Commission approves biosimilar AVT03Dr. Reddy's Laboratories secured European Commission approval for AVT03, a biosimilar to Prolia and Xgeva, for osteoporosis and bone compli...
- Dr Reddy’s gets EC nod for AVT03: New Prolia and Xgeva biosimilar set to launch across EuropeDr. Reddy's Laboratories has secured European Commission marketing approval for AVT03, a biosimilar to Prolia and Xgeva, used for bone-rela...
- Dr Reddy's gets European nod for biosimilar to treat osteoporosisProlia is a prescription medicine used to treat osteoporosis in women who have been through menopause and in men who are at increased risk ...
- Biocon shares rise 2% after USFDA approval for osteoporosis and bone loss drugsShares of Biocon Ltd rose 2% to Rs 361.25 on the BSE after its subsidiary, Biocon Biologics, received U.S. FDA approval for two denosumab b...
- Alvotech, Dr. Reddy's ink pact for commercialisation of denosumabAlvotech and Dr. Reddy's partner for AVT03, a biosimilar to Prolia and Xgeva, treating osteoporosis and skeletal-related events. The agreem...
- Lupin, DKSH enter pact to commercials Alvotech biosimilars in PhilippinesThe biosimilars planned under this agreement include biosimilar Prolia (denosumab 60mg/ml) and Xgeva (denosumab 70 mg/ml) for treating oste...
- Dr Reddy's Laboratories inks pact with Amgen to commercialise three drugs in IndiaUnder the terms, DRL will commercialise Xgeva (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India, a company statement said...
Load More